PLoS ONE (Jan 2013)

Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles.

  • Inger-Lise Mero,
  • Marte W Gustavsen,
  • Hanne S Sæther,
  • Siri T Flåm,
  • Pål Berg-Hansen,
  • Helle B Søndergaard,
  • Poul Erik H Jensen,
  • Tone Berge,
  • Anja Bjølgerud,
  • Aslaug Muggerud,
  • Jan H Aarseth,
  • International Multiple Sclerosis Genetics Consortium,
  • Kjell-Morten Myhr,
  • Elisabeth G Celius,
  • Finn Sellebjerg,
  • Jan Hillert,
  • Lars Alfredsson,
  • Tomas Olsson,
  • Annette Bang Oturai,
  • Ingrid Kockum,
  • Benedicte A Lie,
  • Bettina Kulle Andreassen,
  • Hanne F Harbo

DOI
https://doi.org/10.1371/journal.pone.0058352
Journal volume & issue
Vol. 8, no. 3
p. e58352

Abstract

Read online

The presence of oligoclonal bands (OCB) in cerebrospinal fluid (CSF) is a typical finding in multiple sclerosis (MS). We applied data from Norwegian, Swedish and Danish (i.e. Scandinavian) MS patients from a genome-wide association study (GWAS) to search for genetic differences in MS relating to OCB status. GWAS data was compared in 1367 OCB positive and 161 OCB negative Scandinavian MS patients, and nine of the most associated SNPs were genotyped for replication in 3403 Scandinavian MS patients. HLA-DRB1 genotypes were analyzed in a subset of the OCB positive (n = 2781) and OCB negative (n = 292) MS patients and compared to 890 healthy controls. Results from the genome-wide analyses showed that single nucleotide polymorphisms (SNPs) from the HLA complex and six other loci were associated to OCB status. In SNPs selected for replication, combined analyses showed genome-wide significant association for two SNPs in the HLA complex; rs3129871 (p = 5.7×10(-15)) and rs3817963 (p = 5.7×10(-10)) correlating with the HLA-DRB1*15 and the HLA-DRB1*04 alleles, respectively. We also found suggestive association to one SNP in the Calsyntenin-2 gene (p = 8.83×10(-7)). In HLA-DRB1 analyses HLA-DRB1*15∶01 was a stronger risk factor for OCB positive than OCB negative MS, whereas HLA-DRB1*04∶04 was associated with increased risk of OCB negative MS and reduced risk of OCB positive MS. Protective effects of HLA-DRB1*01∶01 and HLA-DRB1*07∶01 were detected in both groups. The groups were different with regard to age at onset (AAO), MS outcome measures and gender. This study confirms both shared and distinct genetic risk for MS subtypes in the Scandinavian population defined by OCB status and indicates different clinical characteristics between the groups. This suggests differences in disease mechanisms between OCB negative and OCB positive MS with implications for patient management, which need to be further studied.